Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Therapeutic Effect of Local Hypothermia in Treatment of Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:   Procedure: Infusion of Cold Saline into Local Infarction Myocardium.
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting - verified December 2016

Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study

Conditions:   Acute Coronary Syndrome;   STEMI
Interventions:   Drug: Chewing Ticagrelor LD;   Drug: Chewing Prasugrel LD
Sponsor:   Sheba Medical Center
Not yet recruiting - verified January 2017

Coronary Artery Healing and Bioresorbable Scaffold

Conditions:   Myocardial Infarction;   Coronary Artery Disease
Interventions:   Device: OCT guided PCI;   Device: Angiography guided PCI
Sponsor:   Odense University Hospital
Not yet recruiting - verified January 2017

Post-Myocardial Infarction Patients in Santa Catarina, Brazil - Catarina Heart Study

Condition:   Myocardial Infarction
Intervention:   Other: Myocardial Infarction
Sponsor:   Instituto de Cardiologia de Santa Catarina
Enrolling by invitation - verified January 2017

Coronary Artery Plaque Burden and Morphology in Type 2 Diabetes Mellitus.

Conditions:   Type2 Diabetes;   Atherosclerosis;   Plaque, Atherosclerotic;   Plaque Vulnerability;   Diabetes Complications;   Microalbuminuria;   Coronary Computed Tomography Angiography
Intervention:  
Sponsor:   Svendborg Hospital
Recruiting - verified January 2017

NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation

Condition:   Mitral Valve Failure
Interventions:   Device: Edwards SAPIEN 3 transcatheter heart valve;   Device: ASHI INTECC Astato XS 20
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified January 2017

Influence of Age, Weight and Ethnic Background on Blood Pressure

Conditions:   Cardiovascular Diseases;   Vascular Diseases;   Hypertension
Interventions:   Other: Brief lifestyle/medical history questionnaire;   Other: Anthropometric measures;   Other: Blood pressure and arterial stiffness;   Other: Cardiac output and lung function;   Other: Heart rate variability;   Other: Blood sample & spot urine sample;   Other: 24 hour ambulatory blood pressure monitor;   Other: 24 hour urine collection;   Other: Echocardiograph: Left ventricular mass;   Other: Large artery structure: Carotid intima-media thickness;   Other: Small artery structure: Minimum forearm vascular resistance;   Other: Large artery endothelial function;   Other: Small artery endothelial function: Forearm blood flow;   Other: Dundee step test;   Other: Detailed haemodynamic response to submaximal exercise;   Other: Cardiopulmonary fitness: Maximum oxygen consumption;   Other: Haemodynamic response to mental stress
Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   University of Cambridge
Not yet recruiting - verified January 2017

Stanford Healthy Heart Study

Condition:   Obesity
Interventions:   Behavioral: Fun First;   Behavioral: Weight Watchers
Sponsors:   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified January 2017

The Effect of Periodontal Therapy in Chronic Periodontitis Patients With and Without Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Chronic Periodontitis
Interventions:   Procedure: Periodontal examination;   Procedure: GCF sampling;   Procedure: phase I therapy
Sponsors:   Gazi University;   Ankara University
Completed - verified January 2017

Subclinical Hypothyroidism and Acute Anterior Myocardial Infarction: Is it Cardio-protective or Not?

Condition:   Heart Injuries
Interventions:   Other: Echo-cardiogram;   Other: Blood test
Sponsor:   Hillel Yaffe Medical Center
Not yet recruiting - verified January 2017

Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions

Condition:   Percutaneous Coronary Intervention
Intervention:   Other: the prevalence of ischemic events
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified January 2017

Arrhythmia Genetics in the NEtherlandS

Conditions:   Myocardial Infarction First;   Ventricular Fibrillation
Intervention:  
Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrolling by invitation - verified January 2017

Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease

Conditions:   Adverse Effect;   Atherosclerosis, Coronary;   Insulin Resistance Syndrome
Interventions:   Drug: Pioglitazone 15 mg Tablet;   Drug: Isosorbide Dinitrate 10Mg Tablet;   Drug: Acetylsalicylic Acid 75Mg Tablet;   Drug: Bisoprolol Fumarate 2.5 MG Oral Tablet;   Drug: Rosuvastatin Calcium 20 MG Oral Tablet;   Drug: ramipril 5 MG
Sponsor:   Ukrainian Medical Stomatological Academy
Completed - verified January 2017

Remote Ischemic Preconditioning for Cardic Surgery

Conditions:   Myocardial Injury;   Remote Ischemic Preconditioning
Interventions:   Procedure: Remote Ischemic Preconditioning;   Procedure: Control
Sponsor:   Xuzhou Medical University
Not yet recruiting - verified January 2017

Annular Contraction for Transcatheter Treatment of Insufficient Mitral ValvE

Conditions:   Mitral Valve Insufficiency;   Cardiac Valve Annuloplasty;   Mitral Valve Annuloplasty;   Cardiovascular Diseases;   Heart Diseases;   Heart Valve Diseases;   Mitral Regurgitation
Intervention:   Device: Cardioband Mitral System
Sponsor:   Valtech Cardio Ltd
Not yet recruiting - verified January 2017

Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients

Condition:   Primary Hypertension
Interventions:   Drug: Intensive BP control;   Drug: Standard BP control
Sponsor:   Chinese Academy of Medical Sciences, Fuwai Hospital
Recruiting - verified January 2017

Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
Sponsors:   Esperion Therapeutics;   Cleveland Clinic Coordinating Center for Clinical Research (C5 Research)
Recruiting - verified January 2017

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Condition:   Myocardial Infarction
Interventions:   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified January 2017

Brain, Cardiac Hemodynamics and Cognition During Exercise in Subjects With Various Cardiovascular Profiles

Conditions:   Metabolic Syndrome;   Coronary Artery Disease;   Heart Failure
Intervention:   Other: Exercise and Cognitive testing
Sponsor:   Montreal Heart Institute
Active, not recruiting - verified January 2017

Troponin Release Induced by Procedure - Czech

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Tomas Bata Hospital, Czech Republic
Completed - verified January 2017

MET: REevaluation for Perioperative cArdIac Risk (MET-REPAIR)

Condition:   Non Cardiac Surgery
Intervention:  
Sponsor:   European Society of Anaesthesiology
Not yet recruiting - verified January 2017

Cardiac Function and Microcirculation: Type 2 DIABetes and ECHOcardiographic Changes Over Time

Condition:   Left Ventricular Dysfunction
Intervention:  
Sponsor:   Svendborg Hospital
Recruiting - verified January 2017

Phenylephrine and Noradrenaline for Post Spinal Anesthesia Hypotension

Condition:   Adverse Anesthesia Outcome
Interventions:   Drug: phenylephrine;   Drug: Norepinephrine;   Drug: Bupivacaine;   Drug: Fentanyl;   Drug: Placebo (normal saline)
Sponsor:   Kasr El Aini Hospital
Not yet recruiting - verified January 2017

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Condition:   Acute Myocardial Infarction
Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified January 2017

Women's Heart Attack Research Program: Stress Ancillary Study

Condition:   Myocardial Infarction
Interventions:   Behavioral: Enhanced Usual Care;   Behavioral: Stress Management;   Device: Actigraph
Sponsor:   New York University School of Medicine
Recruiting - verified January 2017

Women's Heart Attack Research Program- Imaging Study

Condition:   Myocardial Infarction
Interventions:   Device: OCT;   Other: CMR
Sponsor:   New York University School of Medicine
Recruiting - verified January 2017

China STEMI Care Project Phase 2

Condition:   ST-Elevation Myocardial Infarction
Intervention:   Other: clinical pathway
Sponsors:   Peking University First Hospital;   Chinese Medical Doctor Association
Recruiting - verified January 2017

Bifurcation ABSORB OCT Trial

Conditions:   Myocardial Ischemia;   Ischemia;   Coronary Disease;   Heart Diseases;   Cardiovascular Diseases;   Coronary Bifurcation Lesions;   Arterial Occlusive Lesions;   Infarction;   Myocardial Infarction;   Arteriosclerosis
Intervention:   Device: ABSORB BVS
Sponsors:   J.J. Wykrzykowska;   Abbott Vascular;   St. Jude Medical
Active, not recruiting - verified January 2017

Long-term Remote Ischemic Preconditioning Improve Long-term Prognosis of Acute Myocardial Infarction Patients Without Emergency Reperfusion Therapy

Condition:   Myocardial Infarction
Intervention:   Other: reported remote ischemic preconditioning (RIPC)
Sponsor:   Xuanwu Hospital, Beijing
Not yet recruiting - verified July 2016

Long-term Remote Ischemic Preconditioning Improve the Prognosis of Myocardial Infarction Patients With Emergency Reperfusion Therapy

Condition:   Myocardial Infarction, Acute
Intervention:   Other: remote ischemic preconditioning (RIPC)
Sponsor:   Xuanwu Hospital, Beijing
Not yet recruiting - verified July 2016

LEADERS FREE II: BioFreedom™ Pivotal Study

Conditions:   Acute Coronary Syndrome;   High Bleeding Risk
Interventions:   Device: BioFreedom™ Drug Coated Coronary Stent System;   Drug: Dual Antiplatelet Therapy
Sponsor:   Biosensors Europe SA
Not yet recruiting - verified January 2017

Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention

Conditions:   Myocardial Infarction;   Complications; Device, Vascular;   Injury of Radial Artery;   Injury; Blood Vessel, Femoral, Artery
Interventions:   Procedure: Transradial primary percutaneous coronary intervention;   Procedure: Transfemoral primary percutaneous coronary intervention
Sponsor:   Irmandade Santa Casa Misericórdia Marília
Recruiting - verified January 2017

Actigraphy and Nocturnal Heartrate Variability in Cluster Headache Patients

Conditions:   Cluster Headache;   Sleep
Interventions:   Device: Actigraphy;   Device: Heart-rate variability monitoring;   Device: Pupillometry
Sponsors:   Nordlandssykehuset HF;   University of Tromso
Not yet recruiting - verified January 2017

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

Condition:   Hereditary Angioedema (HAE)
Interventions:   Drug: CINRYZE 500 U;   Drug: CINRYZE 1000 U
Sponsor:   Shire
Recruiting - verified January 2017

Interest of CARE Rule to Exclude the Hypothesis of an Acute Coronary Syndrome Without Bioassay - ICARE

Condition:   Chest Pain
Intervention:   Other: CARE Rule
Sponsor:   University Hospital, Angers
Recruiting - verified January 2017

Angio-based Flow Fractional Reserve to Predict Adverse Events After Stent Implantation

Conditions:   Prognosis;   Stents
Intervention:   Other: angio-based FFR estimation
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2017

Prognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study

Condition:   Coronary Artery Disease
Intervention:   Other: 2year Follow-up
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified January 2017

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

Condition:   Normal Physiology
Interventions:   Drug: Solu-Medrol (methylprednisolone sodium succinate);   Drug: Topical methylprenisolone 0.1%
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2017

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL_112;   Other: Placebo
Sponsor:   CSL Behring
Recruiting - verified January 2017

Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients

Conditions:   Acute Coronary Syndromes;   ST Elevation Myocardial Infarction
Interventions:   Drug: Chewing Ticagrelor;   Drug: Oral Ticagrelor
Sponsor:   Sheba Medical Center
Completed - verified January 2017

PARA-HEART Pilot Implementation

Conditions:   Acute Coronary Syndrome;   Chest Pain
Intervention:  
Sponsor:   Wake Forest University Health Sciences
Recruiting - verified January 2017

Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications

Conditions:   Myocardial Ischemia;   Rheumatic Diseases
Intervention:   Other: Caplan IVR
Sponsor:   VA Office of Research and Development
Recruiting - verified January 2017

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Conditions:   Myocardial Infarction;   Diabetes Mellitus;   Renal Disease;   Coronary Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsors:   University of Patras;   AstraZeneca
Recruiting - verified January 2017

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2016

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Condition:   Carotid Artery Stenosis
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Aspirin
Sponsor:   University Hospital, Basel, Switzerland
Recruiting - verified January 2017

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

Condition:   Prostate Cancer
Interventions:   Drug: Degarelix;   Drug: Leuprolide
Sponsors:   Ferring Pharmaceuticals;   Memorial Sloan Kettering Cancer Center;   Duke Clinical Research Institute
Recruiting - verified January 2017

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Radiometer Medical ApS
Recruiting - verified January 2017

AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions:   Chronic Graft vs Host Disease;   Chronic Graft-Versus-Host-Disease;   Bronchiolitis Obliterans Syndrome
Intervention:   Drug: AZD9668
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2016

Peer Mentored Approaches for Women With Coronary Artery Disease ("4-Steps")

Condition:   Coronary Artery Disease
Interventions:   Behavioral: Peer Mentor;   Behavioral: Transcendental Meditation
Sponsor:   Weill Medical College of Cornell University
Recruiting - verified January 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified January 2017

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified January 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified January 2017

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified January 2017

HYbrid CoronAry Revascularization in DiabeticS

Conditions:   Diabetes;   Heart Disease
Interventions:   Procedure: Treatment;   Procedure: Control
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified January 2017

Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome

Conditions:   Diabetes Mellitus;   Acute Coronary Syndrome;   Coronary Artery Disease
Interventions:   Drug: Novel strategy Aspirin;   Drug: Conventional strategy Aspirin
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Bayer
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified January 2017

CardiAMP™ Heart Failure Trial

Condition:   Heart Failure
Interventions:   Biological: Autologous cell therapy;   Device: CardiAMP cell therapy;   Other: Sham
Sponsor:   BioCardia, Inc.
Recruiting - verified January 2017

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified August 2016

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Active, not recruiting - verified January 2017

Brilinta Taiwan Post Approval Safety Study

Condition:   Non ST-elevation Myocardial Infarction
Intervention:   Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Sponsor:   AstraZeneca
Active, not recruiting - verified January 2017

B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis

Conditions:   Fatigue;   Primary Biliary Cirrhosis
Interventions:   Biological: Rituximab;   Other: Placebo
Sponsors:   Newcastle-upon-Tyne Hospitals NHS Trust;   National Institute for Health Research, United Kingdom;   Department of Health, United Kingdom;   Newcastle University
Completed - verified January 2017

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified January 2017

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified January 2017

Multi-cap for Increase Adherence After Acute Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Other: Combined capsule;   Other: Conventional therapy
Sponsor:   Hospital El Cruce
Terminated - verified January 2017

Research on Infarction With Open Arteries Using OCT and CMR

Condition:   Myocardial Infarction
Interventions:   Device: OCT;   Procedure: CMR;   Drug: contrast agent, Gadolinium
Sponsors:   New York University School of Medicine;   New York University
Recruiting - verified January 2017

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2017

Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees

Condition:   Coronary Artery Disease
Intervention:   Behavioral: Financial incentives
Sponsors:   University of Vermont;   National Institute of General Medical Sciences (NIGMS)
Recruiting - verified January 2017

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified January 2017

Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome

Conditions:   Angina Pectoris;   Acute Myocardial Infarction
Interventions:   Device: iFR;   Device: FFR
Sponsor:   Uppsala University
Completed - verified January 2017

Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides

Condition:   ANCA-associated Primary Necrotizing Vasculitides
Interventions:   Drug: Rosuvastatin;   Drug: Placebo
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified January 2017

Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy

Condition:   Coronary Artery Disease
Intervention:   Device: Angioshield
Sponsor:   Neograft Technologies, Incorporated
Completed - verified January 2017

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)

Conditions:   Hypertension;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2016

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified January 2017

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified January 2017

Post Acute Coronary Event Smoking Study

Conditions:   Smoking Cessation;   Acute Coronary Syndrome
Interventions:   Behavioral: Behavioral Activation (BA);   Behavioral: Standard Smoking Cessation Counseling;   Drug: Nicotine patch;   Other: Printed Self-help materials for Smoking Cessation
Sponsor:   The Miriam Hospital
Completed - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2017

Effectiveness of a Website and Telemonitoring in Patients With Heart Failure.

Condition:   Heart Failure
Interventions:   Other: Educational website (in addition to usual care).;   Other: Website and interactive platform with telemonitoring.
Sponsors:   UMC Utrecht;   Foundation: Zorg Binnen Bereik
Completed - verified January 2017

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Completed - verified January 2017

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Conditions:   Aplastic Anemia;   Neutropenia;   Pancytopenia;   Anemia;   Thrombocytopenia
Interventions:   Drug: Eltrombopag;   Drug: Horse Anti-Thymocyte Globulin (ATG);   Drug: Cyclosporine A (CSA)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2017

Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Modification of Prasugrel based on a biological assay;   Drug: prasugrel / clopidogrel;   Device: Verify Now
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Allies in Cardiovascular Trials Initiatives and Organized;   Accumetrics, Inc.;   Stentys
Completed - verified January 2017

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

Condition:   Acute Myocardial Infarction
Interventions:   Procedure: Post Conditioning + Primary PCI;   Procedure: Standard Primary PCI
Sponsors:   Minneapolis Heart Institute Foundation;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified January 2017

Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Conditions:   Invasive Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer
Intervention:   Drug: Propranolol
Sponsor:   Washington University School of Medicine
Completed - verified January 2017

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Conditions:   High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions:   Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
Sponsors:   Ronald Hoffman;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Roche Pharma AG
Active, not recruiting - verified January 2017

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Conditions:   High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions:   Drug: PEGASYS;   Drug: Aspirin
Sponsors:   Ronald Hoffman;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Roche Pharma AG
Completed - verified January 2017

The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction

Conditions:   Acute Myocardial Infarction;   Ischemia-reperfusion Injury
Interventions:   Drug: Melatonin, N-acetyl-5-methoxytryptamine;   Drug: Isotonic saline, Natrium chloride
Sponsor:   Herlev Hospital
Completed - verified January 2017

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

Condition:   Saphenous Vein Graft Atherosclerosis
Interventions:   Device: Bare Metal Stent;   Device: Drug-Eluting Stent;   Drug: Blinded clopidogrel;   Drug: Placebo;   Drug: Thienopyridine (open-label)
Sponsor:   VA Office of Research and Development
Completed - verified January 2017

PRE-DETERMINE Cohort Study

Conditions:   Coronary Artery Disease;   Left Ventricular Dysfunction;   Sudden Cardiac Death
Intervention:  
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   St. Jude Medical;   Northwestern University;   Roche Diagnostics Corporation;   Quintiles, Inc.
Active, not recruiting - verified January 2017

Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study

Conditions:   End Stage Renal Disease;   Transplantation
Intervention:  
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Health Resources and Services Administration (HRSA)
Completed - verified January 2017

Cardiac FDG PET Viability Registry

Conditions:   Heart Failure;   Ischemic Heart Disease;   Myocardial Dysfunction
Intervention:  
Sponsors:   Ottawa Heart Institute Research Corporation;   Ontario Ministry of Health and Long Term Care
Recruiting - verified January 2017

Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI

Conditions:   Coronary Artery Disease;   Acute Myocardial Infarction
Interventions:   Biological: autologous bone marrow-derived progenitor cells;   Biological: placebo medium
Sponsors:   Johann Wolfgang Goethe University Hospital;   University of Leipzig
Terminated - verified January 2017

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Completed - verified January 2017

PET and Recovery Following Revascularization (PARR 2)

Conditions:   Coronary Artery Disease;   Ventricular Dysfunction, Left
Interventions:   Procedure: Positron emission tomography: FDG viability imaging;   Other: PET imaging
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR);   Heart and Stroke Foundation of Ontario
Completed - verified January 2017